ClinicalTrials.gg
RecruitingNCT05489575Updated Apr 7, 2026

CPAP for the Treatment of Supine Hypertension

An interventional study of Active CPAP and Sham CPAP in Autonomic Failure, Pure Autonomic Failure and Multiple System Atrophy, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if it can be used to treat their high blood pressure during the night. CPAP (a widely used treatment for sleep apnea) involves using a machine that blows air into a tube connected to a mask covering the nose, or nose and mouth, to apply a low air pressure in the airways.

The study includes 3-5 days spent in the Vanderbilt Clinical Research Center (CRC): at least one day of screening tests, followed by up to 3 study days. Subjects may be able to participate in daytime and/or overnight studies. The Daytime study consists of 2 study days: one with active CPAP and one with sham CPAP applied for up to 2 hours. The Overnight study consists of 3 study nights: one with active CPAP, one with sham CPAP, both applied for up to 9 hours and one night sleeping with the bed tilted head-up.

Read the detailed description

The study includes up to 5 days spent in the Vanderbilt University Medical Center, at least one day of screening tests, followed by 2 study days and/or 2 study nights.

Screening tests include a physical examination and history, routine safety laboratory assessments, and autonomic nervous system testing. Medications for high blood pressure will be held for at least 5 half-lives before studies. Subjects may be able to participate in the daytime and/or the overnight studies.

Daytime Study:

Eligible participants will be studied on two separate days in random order: one day with a high CPAP level and one day with a low CPAP level. The active CPAP level will be determined during a CPAP titration trial

On each study day, participants will be instrumented to measure blood pressure, heart rate, hemodynamic parameters, segmental impedance, and markers of cardiovascular risk. A saline lock or IV catheter will be inserted in one of the arm's veins for blood sample collection. Urine will also be collected during studies.

After baseline measurements, active or sham CPAP will then be applied for up to 2 hours. Outcome measurements will be repeated after 1 and 2 hours of CPAP.

Overnight Studies:

Eligible participants will be studied on three separate nights in random order with a active CPAP, sham CPAP, and sleeping in a head-up tilt position. The active CPAP level will be determined during a CPAP titration trial.

On each study night, the intervention (active CPAP, sham CPAP, or head-up tilt position) will be applied for up to 9 hours. Blood pressure, heart rate, hemodynamic parameters, and markers of cardiovascular risk will be assessed throughout the night. Urine will also be collected during this period. On the following morning, participants will have a tilt table test.

02

Conditions studied

  • Autonomic Failure
  • Pure Autonomic Failure
  • Multiple System Atrophy
  • Parkinson Disease
  • Supine Hypertension
  • Neurogenic Orthostatic Hypotension

Keywords

  • CPAP
  • Hypertension
  • Orthostatic hypotension
03

In context

Pure Autonomic Failure

56 studies on the registry are indexed under Pure Autonomic Failure; 10 are open to participants now.

This study's planned enrollment of 59 is above the median of 39 across 41 interventional studies indexed under Pure Autonomic Failure.

Browse Pure Autonomic Failure studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 833 studies on the registry; 155 are open to participants now.

Of its 125 completed or terminated interventional studies of FDA-regulated products, 92 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, age 40-80 years, with autonomic failure including pure autonomic failure, multiple system atrophy and Parkinson disease.
  • Neurogenic orthostatic hypotension, defined as a ≥20-mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.
  • Nocturnal supine hypertension (nighttime systolic blood pressure ≥140 mmHg) during the overnight screening for supine hypertension.
  • Patients who are willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Patients with history of recent facial trauma or surgery or intolerance to CPAP or to the CPAP mask.
  • Patients who cannot tolerate the medication withdrawal, defined as those who are unable to stand for at least one minute or those with sustained supine blood pressure ≥180/110 mmHg after the medication withdrawal period.
  • Bedridden patients or those who are unable to stand due to motor impairment or severe orthostatic hypotension.
  • Smokers, patients who are pregnant, or have clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months; heart failure; and other factors which in the investigator's opinion would prevent the subject from completing the protocol including abnormalities in clinical or laboratory testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    Active CPAP (Daytime Study)

    CPAP at 8, 10, or 12 cm H2O is applied for up to 2 hours while supine and awake.

    Device: Active CPAP

  • Sham comparator
    Sham CPAP (Daytime Study)

    Sham CPAP is applied for up to 2 hours while supine and awake.

    Device: Sham CPAP

  • Experimental
    Active CPAP (Overnight Study)

    CPAP at 8, 10, or 12 cm H2O is applied for up to 9 hours during the night.

    Device: Active CPAP

  • Sham comparator
    Sham CPAP (Overnight Study)

    Sham CPAP is applied for up to 9 hours during the night.

    Device: Sham CPAP

  • Active comparator
    Sleeping in a head-up tilt position (Overnight Study)

    Sleeping with the bed tilted head-up by 10 degrees for up to 9 hours during the night.

    Other: Sleeping in a head-up tilt (HUT) position

Interventions

  • DeviceActive CPAP

    Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial

    Also known as: Active continuous positive airway pressure

  • DeviceSham CPAP

    Sham continuous positive airway pressure applied at \<4 cm H2O

    Also known as: Sham continuous positive airway pressure

  • OtherSleeping in a head-up tilt (HUT) position

    Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.

    Also known as: HUT sleeping

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure (daytime)

    Change from baseline in systolic blood pressure at 2 hours of the intervention

    Time frame: day 1 and 2 (within 2 hours of the intervention)

  2. Systolic blood pressure (overnight)

    Area under the curve of the change from baseline in systolic blood pressure

    Time frame: up to 9 hours during the intervention

Secondary outcomes

  1. Stroke Volume (daytime)

    Change from baseline in stroke volume at 1and 2 hours of the intervention

    Time frame: day 1 and 2 (within 2 hours of the intervention)

  2. Natriuretic hormone (daytime)

    Percent change from baseline in N-terminal-proatrial natriuretic peptide at 2 hours after the intervention

    Time frame: day 1 and 2 (within 2 hours of the intervention)

  3. Nocturnal diuresis (overnight)

    Urine volume collected during the night

    Time frame: up to 9 hours during the intervention

  4. Morning orthostatic tolerance (overnight)

    Area under the curve of the upright systolic blood pressure during head-up tilt

    Time frame: during 10 minutes upright tilt

07

Study locations

1 of 1 sites recruiting
  • Autonomic Dysfunction Center/ Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Bonnie K Black, RN, NP · Contactbonnie.black@vumc.org · 615-343-6862
    • Luis E Okamoto, MD · Contactluis.e.okamoto@vumc.org · (615) 936-6119
    • Andre Diedrich, MD, PhD · Sub investigator
    • Alfredo Gamboa, MD · Sub investigator
    • Cyndya A Shibao, MD · Sub investigator
    • Italo Biaggioni, MD · Principal investigator
    • Luis E Okamoto, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05489575
Responsible party
Italo Biaggioni (Professor of Medicine and Pharmacology, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 5, 2022
Start date
Jun 23, 2022
Primary completion
Mar 1, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Bonnie K Black, RN, NP
Contact
bonnie.black@vumc.org
615-343-6862
Luis E Okamoto, MD
Contact
luis.e.okamoto@vumc.org
615-936-6119
Italo Biaggioni, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion